Mink Therapeutics stock tumbles on $50 million stock offering
Investing.com -- Mink Therapeutics Inc (NASDAQ:INKT) stock plunged 21% after the company announced plans to sell up to $50 million of its common stock through an at-the-market (ATM) equity offering program.
The biotech company disclosed in a prospectus supplement that it has entered into an ATM Sales Agreement with B. Riley Securities, Inc., which will act as the sales agent for the offering. Under the terms of the agreement, Mink Therapeutics may offer and sell shares of its common stock, with a par value of $0.00001 per share, from time to time.
The significant stock decline reflects typical investor reaction to potential dilution from new share issuances. When companies announce large equity offerings relative to their market capitalization, existing shareholders often face dilution of their ownership stakes, putting downward pressure on the stock price.
The timing and actual number of shares to be sold through the ATM program will depend on various factors, including market conditions, as determined by the company in coordination with its sales agent.
Mink Therapeutics has not specified how it intends to use the proceeds from the potential stock sales, though biotechnology companies typically raise capital to fund research and development activities, clinical trials, or general corporate purposes.
The company’s stock offering comes amid challenging market conditions for small-cap biotech firms, many of which have turned to equity offerings to strengthen their balance sheets and fund ongoing operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
